<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Treat Options Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Curr Treat Options Infect Dis</journal-id><journal-title-group><journal-title>Current Treatment Options in Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1523-3820</issn><issn pub-type="epub">1534-6250</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7366488</article-id><article-id pub-id-type="publisher-id">235</article-id><article-id pub-id-type="doi">10.1007/s40506-020-00235-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Hepatitis C (J Raybould, Section Editor)</subject></subj-group></article-categories><title-group><article-title>A Review of the Diagnosis and Management of Hepatitis E</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kar</surname><given-names>P.</given-names></name><address><email>premashishkar@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Karna</surname><given-names>R.</given-names></name><address><email>rahulkarnagovind@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.459746.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1805 869X</institution-id><institution>Department of Gastroenterology and Hepatology, </institution><institution>Max Super Specialty Hospital,Ghaziabad, </institution></institution-wrap>Delhi, New Delhi 110017 India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.414698.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1767 743X</institution-id><institution>Maulana Azad Medical College &#x00026; Lok Nayak Hospital, </institution></institution-wrap>Bahadurshah Zafar Road, New Delhi, India </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>7</month><year>2020</year></pub-date><fpage>1</fpage><lpage>11</lpage><permissions><copyright-statement>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of review</title><p id="Par1">We aim to provide the readers an up-to-date knowledge of the structure, epidemiology, and transmission followed by a detailed discussion on testing, diagnostics and management of hepatitis E virus infection. We have also included a comprehensive review of hepatitis E in pregnancy.</p></sec><sec><title>Recent findings</title><p id="Par2">European Association for the Study of the Liver established clinical practice guidelines for testing and treatment of suspected hepatitis E virus infections in 2018. Evidence suggests chronic hepatitis E may follow a course similar to hepatitis B/C with progression to cirrhosis and possibly hepatocellular carcinoma in immunocompromised patients.</p></sec><sec><title>Summary</title><p id="Par3">Hepatitis E virus is the most common cause of acute viral hepatitis worldwide. A combination of serology and nucleic acid amplification testing is the recommended strategy for suspected patients. Ribavirin therapy for a period of 3&#x000a0;months is the drug of choice for severe acute hepatitis, acute-on chronic liver failure, and chronic infections from hepatitis E virus in immunocompromised patients who are unresponsive to decreased immunosuppression. PEGylated interferon &#x003b1; can be used for ribavirin-resistant liver transplant patients with chronic hepatitis E. Further research in therapeutic options is essential considering the stormy course of hepatitis E infection during pregnancy and teratogenicity of all available options.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatitis E virus</kwd><kwd>Ribavirin</kwd><kwd>Pregnancy</kwd><kwd>Viral hepatitis</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Hepatitis E virus (HEV) causes acute hepatitis and acute liver failure (ALF) and is the most common cause of acute viral hepatitis worldwide. It was discovered in the early 1980s when sera of patients suspected of viral hepatitis during an outbreak in Kashmir province of India tested negative for hepatitis A and B [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. This enterically transmitted non-A non-B hepatitis virus was termed as hepatitis E virus, with &#x0201c;<bold>E</bold>&#x0201d; standing for its association with epidemics and enteric mode of transmission. The article aims to provide the readers with up-to-date knowledge and recent advances in the clinical aspects of hepatitis E virus infection focusing mainly on diagnostics and management options.</p><sec id="Sec2"><title>Structure of HEV</title><p id="Par5">HEV is a member of the Orthohepevirus genus and belongs to the Hepeviridae family. It is a small, non-enveloped 27&#x02013;34-nm diameter particle with an icosahedral capsid. The virus was first isolated in the 1980s, from stool suspension of HEV-infected patients, and the excreted form of HEV in stool was found to be non-enveloped [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Recently, enveloped forms of the virus have been identified in the blood of patients during viremia [<xref ref-type="bibr" rid="CR5">5</xref>]. The virus gets enveloped in the membrane obtained from the host cell [<xref ref-type="bibr" rid="CR5">5</xref>]. The enveloped virus particles do not get neutralized by antibodies and help the virus survive in the host [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">The virus genome is 7.2&#x000a0;kb, linear, single-stranded, positive-sense RNA, with a 7-methylguanine cap at 5&#x02032; end, 3 open reading frames, namely, <italic>orf 1&#x02013;3</italic>, in between and a poly adenine tail at the other end. ORF 1 is responsible for encoding nonstructural proteins, responsible for RNA replication including RNA helicase and RNA-dependent RNA polymerase [<xref ref-type="bibr" rid="CR6">6</xref>]. ORF2 encodes structural proteins responsible for viral capsid formation [<xref ref-type="bibr" rid="CR6">6</xref>]. These structural proteins represent antigenic sites against which immune response can develop, hence are potential antigens for vaccine development [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. ORF3 protein is found in blood-borne enveloped HEV particles only, responsible for viral replication, survival, and extrusion from the host cell [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec3"><title>Epidemiology</title><p id="Par7">HEV infection occurs throughout the world but predominantly is associated with waterborne outbreaks in Asia and Africa [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. There are seven genotypes of HEV, viz. HEV 1&#x02013;7, but only a single serotype. HEV 1&#x02013;4 are known to infect humans, while HEV 5&#x02013;7 have animals as their host only. There are two different epidemiological patterns of HEV. HEV genotypes 1 and 2 cause outbreaks, mostly in hyperendemic regions of the world. Mostly young adults are affected, and the disease is particularly troublesome for pregnant women who develop a very severe form of the disease [<xref ref-type="bibr" rid="CR11">11</xref>&#x02022;&#x02022;]. Genotype 1 causes outbreaks in Asia (south, southeast, and central) and North Africa while genotype 2 is usually located in Mexico and western parts of Africa [<xref ref-type="bibr" rid="CR12">12</xref>&#x02022;]. Using epidemiological tools and mathematical models, it has been estimated that HEV 1 and HEV 2 cause together approximately 20.1 million (95% credible interval 2.8&#x02013;37.0 million) cases in Asia and Africa, with acute hepatitis E accounting for 3.4 million cases [<xref ref-type="bibr" rid="CR13">13</xref>]. HEV infection is also estimated to cause 70,000 deaths from acute liver failure and ~&#x02009;3000 stillbirths [<xref ref-type="bibr" rid="CR13">13</xref>]. In the developed parts of the world, such as Europe, the USA, and some high-income areas in Asia, the infection is predominantly caused by HEV 3 [<xref ref-type="bibr" rid="CR12">12</xref>&#x02022;]. HEV 4 usually causes infection in China and Japan [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec4"><title>Transmission</title><p id="Par8">Outbreaks from genotype 1 and 2 occur through the fecal-oral route due to fecal contamination of drinking water [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. HEV 3 and HEV 4 cause only sporadic cases in less endemic parts of the world, mostly from direct or indirect animal contacts, and consumption of undercooked animal products [<xref ref-type="bibr" rid="CR11">11</xref>&#x02022;&#x02022;]. Undercooked or raw pork meat, liver, and infected cow&#x02019;s milk are some known sources of HEV infection in these regions [<xref ref-type="bibr" rid="CR12">12</xref>&#x02022;]. Though relatively less common, person to person transmission of HEV is also known. It occurs through transfusion of blood, blood products, solid organ transplant, and via vertical transmission [<xref ref-type="bibr" rid="CR16">16</xref>&#x02022;, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02022;]. Transfusion-transmitted HEV infection accounts for &#x0003c;&#x02009;1% of all HEV infections in the UK [<xref ref-type="bibr" rid="CR12">12</xref>&#x02022;]. Many other European nations, China, and Japan have reported cases of transfusion-transmitted HEV caused by genotypes 3 and 4 predominantly [<xref ref-type="bibr" rid="CR19">19</xref>&#x02022;, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Transfusion-transmitted HEV infection usually causes an asymptomatic or mild infection but may cause chronic infection in immunocompromised individuals [<xref ref-type="bibr" rid="CR21">21</xref>]. Vertical transmission of HEV causes adverse effects on fetus including intrauterine demise or neonatal mortality. Khurro et al. first demonstrated evidence of vertical transmission in 5 out of 8 babies in mothers who developed HEV infection during the third trimester [<xref ref-type="bibr" rid="CR22">22</xref>]. In another study, Kumar et al. demonstrated 100% transmission rates from HEV-infected mothers to fetus [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec5"><title>HEV testing</title><sec id="Sec6"><title>Who should be tested?</title><p id="Par9">European Association for the Study of the Liver (EASL) recommends considering HEV infection as a cause of viral hepatitis and as an important differential diagnosis to drug-induced liver injury in all patients [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;]. Also, people with hepatitis returning from areas endemic to HEV genotype 1 and 2 should be tested. Certain population groups like pregnant women, immunocompromised-like malignancy, and people on immunosuppressants are at high risk for devastating liver disease from HEV infection. Hence, it is imperative to test them upon suspicion of viral hepatitis. EASL recommends testing for HEV during flares up of chronic liver disease and immunocompromised patients or blood recipients with abnormal LFTs [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;]. In many countries around the world, either universal screening of blood or targeted screening for the high-risk recipient is being done. EASL recommends screening blood donors for HEV by nucleic acid amplification testing (NAT) [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;]. Also, HEV has extrahepatic manifestations, including neurologic, renal, hematological, and pancreatic injury. EASL recommends testing for HEV as a causative agent for neuralgia amyotrophy and Guillain-Barre syndrome and suggested testing for encephalitis/myelitis [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;].</p></sec><sec id="Sec7"><title>Diagnostic tests</title><p id="Par10">Since the research work in the field of HEV infection picked up in the last 20&#x000a0;years, diagnostic testing for HEV infection has become more refined. However, it is still marred with a lack of commercial kits in many parts of the world, non-standardization of the diagnostics, and wide variability in the results achieved. In the USA, no testing kit has been licensed for commercial usage.</p><p id="Par11">The diagnosis of HEV infection can be established through direct or indirect testing. The direct tests aim to detect either HEV ribonucleic acid (RNA) or viral capsid antigens in the blood. Since they detect parts of the viral particles itself, the specificity of these tests is usually high, but sensitivity is low. The indirect tests are based upon human immune response against HEV particles, i.e., anti-HEV antibodies. Hence, these tests usually have high sensitivity but low specificity. A summary of available tests for HEV infection is represented in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>A summary of available tests for HEV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Test name</th><th>Time from infection to positive</th><th>Duration of clinical usefulness</th><th>Sensitivity</th><th>Specificity</th><th>Comments</th></tr></thead><tbody><tr><td>Anti-HEV IgM</td><td>~&#x02009;4&#x000a0;weeks</td><td>6&#x02013;9&#x000a0;months</td><td><p>Immunocompromised:85&#x02013;87.5%</p><p>Immunocompetent: 80&#x02013;90%</p></td><td>&#x02265;&#x02009;99.5%</td><td>Usually first test to be considered</td></tr><tr><td>Anti-HEV IgG</td><td>~&#x02009;4&#x000a0;weeks</td><td>years</td><td><p>Immunocompromised:15&#x02013;45%</p><p>Immunocompetent: 80&#x02013;90%</p></td><td>89&#x02013;98%</td><td>Useful for seroepidemiological studies; not clinically useful</td></tr><tr><td>HEV Capsid antigen</td><td>~&#x02009;2&#x000a0;weeks</td><td>4&#x02013;5&#x000a0;weeks</td><td>88&#x02013;99%</td><td>100%</td><td>Low cost and easy to perform; can be considered for blood screening</td></tr><tr><td>HEV RNA</td><td>~&#x02009;2&#x000a0;weeks</td><td>4&#x02013;5&#x000a0;weeks</td><td>&#x02013;</td><td>&#x02013;</td><td>Gold standard test; useful in immunocompromised and seronegative patients</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>Indirect tests</title><p id="Par12">The indirect tests for HEV rely upon the human immune response to generate antibodies against antigenic proteins of HEV. The antigenic proteins used in the assays are recombinant ORF2 and/or ORF3 protein of viral capsid, from HEV 1 genotype [<xref ref-type="bibr" rid="CR25">25</xref>]. Both IgM and IgG types of antibodies can be detected in these patients; however, the performances and validity of both assays are under question [<xref ref-type="bibr" rid="CR26">26</xref>]. IgM anti-HEV antibodies develop nearly 4&#x000a0;weeks after the infection and can be detected in the sera for nearly 6&#x000a0;months, hence indicating an acute or recent infection from HEV. IgG antibodies usually also develop simultaneously with IgM antibodies early after the infection and last for years, indicating either a recent or past infection [<xref ref-type="bibr" rid="CR27">27</xref>]. The utility of these assays is limited by their non-standardization and discordance between different kits. Sometimes, in a subset of the infected population, both IgM and IgG antibodies may be negative in HEV RNA-positive patients [<xref ref-type="bibr" rid="CR4">4</xref>]. Also, these antibodies may wane with time, thus limiting their role for diagnostic and epidemiological purposes [<xref ref-type="bibr" rid="CR28">28</xref>]. In a study by Abranavel et al., the specificity of IgM anti-HEV was &#x02265;&#x02009;99.5% while the specificity of IgG anti-HEV was 89.5% and 97.8% for two different diagnostic kits [<xref ref-type="bibr" rid="CR29">29</xref>]. The testing kits for the detection of IgM antibodies had a higher sensitivity of 80&#x02013;90% in immunocompetent while it was lower among immunocompromised patients viz. 85&#x02013;87.5% [<xref ref-type="bibr" rid="CR29">29</xref>]. The sensitivity of IgG detection kits among immunocompetent patients was 80&#x02013;90% while it fell dramatically to 15&#x02013;45% in immunocompromised patients, rendering the test practically useless [<xref ref-type="bibr" rid="CR29">29</xref>]. Also, there was no correlation between HEV RNA levels and IgG anti-HEV antibody levels [<xref ref-type="bibr" rid="CR29">29</xref>]. The limits of detection of various anti-HEV IgG detection kits available commercially worldwide vary from 0.25 to 2.5 World Health Organization (WHO) units per ml. Using assays with a lower detection limit of 0.25 WHO units per ml gives a more elaborate estimation of the prevalence of HEV infection [<xref ref-type="bibr" rid="CR30">30</xref>]. National Institute for Biological Standards and Control established the WHO reference reagent for HEV detection kit. Experts have suggested that waning anti-HEV IgG antibody levels after the natural course of disease or vaccination could pose a risk for reinfection [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par13">Rapid, technically simpler, cheaper alternatives to serological or RNA-based tests have been gaining attention in recent times. Using IgM capture format, an immunochromatographic assay for detecting IgM anti-HEV antibodies have been developed (ASSURE&#x000ae; HEV IgM Rapid Test; MP Biomedical, Singapore) [<xref ref-type="bibr" rid="CR32">32</xref>]. It has a sensitivity of 93% and specificity of 99.7%, established based upon data obtained from a study in Nepal and Indonesia (Genotype1) [<xref ref-type="bibr" rid="CR32">32</xref>]. While, in another study, during a predominant genotype 3 infection in France, the kit showed sensitivity and specificity of 82% and 100% respectively [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec></sec><sec id="Sec9"><title>Direct tests</title><sec id="Sec10"><title>HEV RNA</title><p id="Par14">HEV RNA detection in blood or stool is the gold standard for the detection of HEV infection. It becomes detectable even before the patient becomes clinically symptomatic and may persist for nearly 4&#x000a0;weeks in the blood and 6&#x000a0;weeks in the feces [<xref ref-type="bibr" rid="CR12">12</xref>&#x02022;]. Most commercially available assays for detecting HEV RNA are based upon NAT. These NAT-based assays include reverse transcriptase polymerase chain reaction (RT-PCR), real-time PCR, and loop-mediated isothermal amplification assay [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The real-time RT-PCR methods are more sensitive than nested RT-PCR methods [<xref ref-type="bibr" rid="CR36">36</xref>]. These methods employ amplification of specific genome sequences mostly ORF3, followed by a nucleotide probe [<xref ref-type="bibr" rid="CR37">37</xref>]. The limit of detection of available RNA probes is 7&#x02013;80&#x000a0;IU/ml [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Characterization of HEV genotypes or subgenotypes is mostly used for epidemiological purposes, and their clinical significance is yet to be determined. Even though it is the most specific method of establishing HEV infection, its utility is mostly limited by high cost, the requirement of specialized tools and expertise, and limited resources in areas with a high burden of the disease. Subject experts and gastroenterologists have suggested HEV RNA testing in the following clinical scenarios [<xref ref-type="bibr" rid="CR4">4</xref>]:<list list-type="order"><list-item><p id="Par15">Blood screening</p></list-item><list-item><p id="Par16">Suspected chronic HEV infection with negative serology</p></list-item><list-item><p id="Par17">Non-hepatic presentations to confirm infection</p></list-item><list-item><p id="Par18">HEV infection diagnosis in immunocompromised patients, with negative serology</p></list-item><list-item><p id="Par19">Monitoring response to antivirals</p></list-item><list-item><p id="Par20">Before genotyping and for epidemiological purposes</p></list-item></list></p></sec><sec id="Sec11"><title>Capsid antigen detection</title><p id="Par21">Viral capsid antigen can be detected in the blood of those infected with HEV even before the patient becomes clinically symptomatic and persists for approximately 4&#x000a0;weeks. Testing for capsid antigen is technically less demanding and can be performed even without molecular detection laboratories. It can be detected using an indirect sandwich enzyme immunoassay, with an estimated sensitivity of 91% and specificity of 100% [<xref ref-type="bibr" rid="CR38">38</xref>]. Studies have demonstrated waning levels of capsid antigen in blood of patients with HEV infection correlated with rising levels of anti-HEV antibodies [<xref ref-type="bibr" rid="CR39">39</xref>]. Thus, it has a lower sensitivity for the detection of acute infection than HEV RNA and IgM anti-HEV [<xref ref-type="bibr" rid="CR39">39</xref>]. However, ease of performing the diagnosis combined with a lower cost than RNA detection makes it an attractive option for blood screening and in early diagnosis of HEV infection.</p></sec><sec id="Sec12"><title>Recommendations</title><p id="Par22">Experts suggest testing for anti-HEV IgM initially for suspected HEV infection [<xref ref-type="bibr" rid="CR12">12</xref>&#x02022;]. A positive test suggests recent or active infection, after which HEV RNA analysis can be done for molecular characterization, while negative test results rule out the disease. The recommended algorithm differs slightly in immunocompromised patients considering the weakened immune response that develops in these patients. Patients who test negative for IgM anti-HEV should be tested for HEV RNA. Positive results for either HEV RNA or anti-HEV IgM confirms recent or active infection, but negative results for both the tests are required to rule out a disease. Also, since immunocompromised patients are at high risk of developing chronic HEV infection, HEV RNA testing in both blood and stools must be done to determine viral clearance before the patient is declared free from infection.</p></sec></sec><sec id="Sec13"><title>Treatment</title><p id="Par23">Management of HEV infection depends upon its clinical presentation. The spectrum of clinical presentation ranges from asymptomatic infections through icteric and anicteric acute hepatitis to chronic hepatitis or liver failure. HEV infection is usually a self-limiting infection, and complete resolution is seen usually without any antiviral therapy. The management of icteric or anicteric viral hepatitis is mostly conservative and focuses on self-resolution of the disease. However, HEV may have a stormy course of disease in the form of ALF, more so in pregnant women. Interestingly, a study by Shalimar et al. has revealed HEV ALF to have lower rates of cerebral edema, infections, seizures, and mortality as compared to other causes of ALF [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par24">In recent years, ribavirin has gained some spotlight in the treatment of HEV infection. Ribavirin, a prodrug, is a guanosine analog and when metabolized acts as a nucleotide analog to deplete intracellular guanosine triphosphate and, subsequently, RNA replication. It has also been postulated that ribavirin acts by inhibiting viral replication and has a role in immune modulation, increased expression of interferon stimulation genes, and mutagenesis [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. There have been reports of improvement in patients with severe acute hepatitis E with treatment with ribavirin [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Hence, ribavirin therapy can be considered for severe acute hepatitis or acute-on chronic liver failure [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;]. Limited evidence with ribavirin suggests a rapid improvement in liver enzyme profile and a decline in HEV RNA levels in patients with HEV genotype 1 and 3 infections. However, its usage in patients with severe acute hepatitis E is based upon anecdotal evidence only.</p><p id="Par25">The existence of chronic HEV infection was first reported in 2008 among solid organ transplant patients [<xref ref-type="bibr" rid="CR45">45</xref>]. Chronic HEV infection is seen clinically in immunosuppressed patients especially with defective T cell response arm, including patients on immunosuppressant for organ transplants, HIV, and hematological malignancies [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref>]. Chronic HEV infection is defined as the detection of HEV RNA in blood or stools or any other body fluids for more than 6&#x000a0;months [<xref ref-type="bibr" rid="CR11">11</xref>&#x02022;&#x02022;]. Nearly, 10% of immunosuppressed chronic HEV-infected patients developed fibrosis and chronic liver disease within a few years [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. Recently, a case of hepatocellular carcinoma in a patient with HEV-associated cirrhosis has been described [<xref ref-type="bibr" rid="CR50">50</xref>&#x02022;].</p><p id="Par26">The management of chronic HEV infection in immunocompromised requires careful assessment of risks and benefits. The first-line management option in such cases is to boost immune response either by reducing the dose of immunosuppressant or initiating antiretroviral therapy along with HEV RNA monthly monitoring for 3&#x000a0;months [<xref ref-type="bibr" rid="CR12">12</xref>&#x02022;]. This the preferred approach and is successful in nearly 33% of patients but must be balanced against the possibility of solid organ rejection [<xref ref-type="bibr" rid="CR49">49</xref>]. In case the risks of reducing immunosuppressants outweigh the benefits, or the first-line option fails, oral ribavirin is the drug of choice, usually administered initially for a period of 3&#x000a0;months. In a retrospective study analyzing the efficacy of ribavirin among 59 transplant patients with chronic hepatitis E, drug ribavirin administered in a median dose of ~&#x02009;8.1&#x000a0;mg/kg for 3&#x000a0;months led to a sustained virological response in 78% patients [<xref ref-type="bibr" rid="CR51">51</xref>]. Sustained virological response is defined as undetectable serum HEV RNA at 6&#x000a0;months after stopping ribavirin. A fall in HEV RNA &#x02265;&#x02009;0.5 log <sub>10</sub> copies/ml on day 7 of ribavirin is said to be a predictor of sustained virological response [<xref ref-type="bibr" rid="CR52">52</xref>]. However, the study did not show any difference in sustained virological response between those treated for &#x02264;3&#x000a0;months from those treated for &#x0003e;&#x02009;3&#x000a0;months [<xref ref-type="bibr" rid="CR51">51</xref>]. Hence, patients with solid organ transplants who fail to clear HEV RNA within 3&#x000a0;months can be considered for ribavirin treatment. Moreover, the patients who relapsed exhibited sustained virological response after treatment with ribavirin for 6 more months [<xref ref-type="bibr" rid="CR51">51</xref>]. Though the exact dose and duration of ribavirin therapy for chronic HEV infection is not defined, treatment courses of 3 to 6&#x000a0;months are typically used. Since chronic hepatitis E patients frequently suffer from anemia and kidney disease and ribavirin pharmacokinetics depend on kidney function, the dose and duration of the therapy must be adjusted according to hemoglobin and eGFR levels in these patients [<xref ref-type="bibr" rid="CR53">53</xref>]. EASL recommends treating patients with chronic HEV and glomerular diseases with antivirals [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;]. Also, ribavirin resistance is now being reported with increasing frequency in patients with chronic hepatitis E due to G1634R mutation in RNA polymerase [<xref ref-type="bibr" rid="CR54">54</xref>]. In an in vitro system, ribavirin shows a synergistic effect with mycophenolate, which is an inosine monophosphate dehydrogenase inhibitor in depreciating HEV RNA replicative machinery; however, no such evidence has been found in vivo till date [<xref ref-type="bibr" rid="CR55">55</xref>].</p><p id="Par27">Sofosbuvir, a nucleotide analog that brought revolutionary changes in the treatment of the hepatitis C virus, has been found to decrease genotype 3 HEV replication in vitro [<xref ref-type="bibr" rid="CR56">56</xref>]. Valk et al. reported a case of chronic hepatitis E in an immunocompromised patient where sofosbuvir showed antiviral activity [<xref ref-type="bibr" rid="CR57">57</xref>&#x02022;]. Wezel et al. observed that sofosbuvir showed antiviral activity in chronic HEV-infected three solid organ transplant patients but failed to achieve sustained virological response [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par28">Interferon &#x003b1; (IFN&#x003b1;) is another therapeutic option for chronic hepatitis E and has shown efficacy in achieving a sustained virological response in patients with liver transplants and hemodialysis [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>]. However, IFN&#x003b1; is contraindicated in patients with transplant recipients due to the risk of acute rejection [<xref ref-type="bibr" rid="CR62">62</xref>]. Limited evidence exists for the treatment of chronic HEV infection in HIV or hematological disease with IFN&#x003b1;, ribavirin, or both, which could form the template for further research and clinical trials to determine the dose, route, and efficacy of available treatment options. In a case report, corticosteroids were associated with biochemical recovery in patients with HEV infection and may prevent the progression of severe hepatitis to liver failure [<xref ref-type="bibr" rid="CR63">63</xref>].</p></sec><sec id="Sec14"><title>HEV in pregnancy</title><p id="Par29">HEV infection in pregnancy caused by genotypes 1 and 2 in developing countries has been associated with poor fetal-maternal outcomes as compared to the relatively benign course of illness in the Western world where infections are more commonly caused by genotypes 3 and 4 [<xref ref-type="bibr" rid="CR64">64</xref>&#x02022;]. Data from our previous study shows HEV infection to have a higher incidence, severe and aggressive course of illness, and poor outcomes during pregnancy [<xref ref-type="bibr" rid="CR65">65</xref>]. In pregnant women, HEV was the leading cause of acute viral hepatitis and acute liver failure accounting for 80.36% (442/550) and 73.38% (102/139) of cases, respectively. HEV-related liver infection accounted for 98/129 (75.96%) death cases, whereas non-HEV liver infection accounted for 31/129 (24.04%) death cases in comparison among pregnant women. The course of illness is worse if the infection is acquired in the third trimester of pregnancy [<xref ref-type="bibr" rid="CR64">64</xref>&#x02022;]. Maternal mortality varies from 15 to 25% for genotype 1 infection acquired in the third trimester [<xref ref-type="bibr" rid="CR66">66</xref>]. Life-threatening complications of ALF viz. coagulopathy, DIC, encephalopathy, and cerebral edema can be seen in 70% of HEV-infected pregnant women [<xref ref-type="bibr" rid="CR67">67</xref>]. An interesting study from Egypt showed high anti-HEV prevalence (84.3%) among pregnant women, but many of them never recalled an episode of viral hepatitis [<xref ref-type="bibr" rid="CR68">68</xref>]. The differences in severity and prognosis in the different parts of the world could be accounted for by infections caused by different genotypes, differences in the rates of childhood infections, healthcare facility, and maternal nutritional state.</p><p id="Par30">Fetal complications of HEV infection range from preterm delivery, intrauterine death, and poor infant survival rates [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. In a study from India, it was observed that 56% of infants born to HEV-infected mothers die in utero or soon after birth [<xref ref-type="bibr" rid="CR10">10</xref>]. In another study, the authors observed that 15 to 50% of such infants die within a week of birth [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. In a study by Rayis et al., out of 39 pregnant women with HEV infection, there were 14 intrauterine deaths and 9 premature deliveries [<xref ref-type="bibr" rid="CR72">72</xref>]. In a retrospective study by Banait et al. among 42 pregnant women with HEV-induced ALF, 23 women could not survive [<xref ref-type="bibr" rid="CR73">73</xref>]. Out of 42 women, 22 delivered with spontaneous delivery in 13 women and induction of labor in 9 women for intrauterine demise [<xref ref-type="bibr" rid="CR73">73</xref>]. The study showed better outcomes in terms of survival among women with encephalopathy who delivered [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par31">Currently, the management of HEV infection in pregnancy is mainly supportive. The use of ribavirin and PEGylated IFN&#x003b1; among pregnant women with HEV has not been explored due to the high risks of teratogenicity. In recent times, the increasing interest in sofosbuvir for HEV in pregnancy is something to look out for, since it is a pregnancy category B drug [<xref ref-type="bibr" rid="CR64">64</xref>&#x02022;]. Also, termination of pregnancy is useful in immunologically mediated liver failures in pregnancy such as HELLP syndrome and acute fatty liver of pregnancy (AFLP). Currently, there is no evidence of any therapeutic benefit of termination of pregnancy in HEV-induced ALF. EASL recommends treatment of HEV genotypes 1 and 2 infections during pregnancy in high-dependency units and prompt transfer to Liver Transplant Unit if liver failure develops [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;]. Liver transplant for HEV-induced ALF during pregnancy is rare, and outcome, complications, and timing of delivery in such a scenario remain unexplored.</p></sec><sec id="Sec15"><title>HEV prevention</title><p id="Par32">Since HEV infection is water and foodborne in hyperendemic and low endemic areas respectively, preventive strategies are focused on preventing water and food contamination. In hyperendemic areas of the world, preventive measures focus on improvement in drinking water quality via chlorination and sanitation hygiene. In low endemicity areas, safe food handling and thorough cooking are the cornerstones of preventing food-based transmission. Immunosuppressed and chronic liver disease patients are advised to refrain from eating raw, undercooked meat, and shellfish [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;]. It has been recommended to cook meat thoroughly at temperatures of 70&#x000a0;&#x000b0;C and above before consumption [<xref ref-type="bibr" rid="CR24">24</xref>&#x02022;&#x02022;].</p><p id="Par33">There has been a considerable amount of research in the past 20&#x000a0;years in the field of HEV vaccination. One of the structural proteins, orf2, responsible for capsid formation, represents antigenic sites against which immune response can develop. Different strains of HEV share neutralizing epitopes on orf2 capsid proteins, thus providing cross-reactivity and potential antigens for vaccine development [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. The first HEV vaccine to be tested in randomized, double-blind, controlled, phase II trial among 2000 Nepalese men showed 95.5% protection during a median follow up of 804&#x000a0;days [<xref ref-type="bibr" rid="CR75">75</xref>]. The vaccine contained a 56-kilo Dalton truncated (amino acid 112&#x02013;607) <italic>orf2</italic> protein administered in three doses at 0&#x02013;1&#x02013;6&#x000a0;months [<xref ref-type="bibr" rid="CR75">75</xref>]. The vaccine did not undergo further development. Another vaccine called HEV 239 (Hecolin&#x000ae;), tested in a double-blind, controlled, randomized phase III trial among 112,604 healthy men and women, is available commercially in China since 2012 [<xref ref-type="bibr" rid="CR76">76</xref>]. The vaccine contains 26&#x000a0;k Dalton recombinant, truncated (amino acid 368&#x02013;606) <italic>orf2</italic> protein, administered 30&#x000a0;&#x003bc;g intramuscularly at 0&#x02013;1&#x02013;6&#x000a0;months, and showed a protection rate of 95.5% after a year and cross-protection for HEV 1 and 4 [<xref ref-type="bibr" rid="CR76">76</xref>]. Long-term follow up of the recruited subjects has shown the vaccine to be protective even after 4&#x000a0;years and safe in women [<xref ref-type="bibr" rid="CR77">77</xref>]. However, the vaccine is not available in other countries. The 30th Global Advisory Committee on Vaccine Safety, WHO has recommended a phase IV trial of the vaccine and further data on its safety in special population groups including children and elderly [<xref ref-type="bibr" rid="CR78">78</xref>]. Experts recommend selective vaccination against HEV in certain high-risk groups such as immunosuppressed population, persons with chronic liver disease, pregnant women in disease-endemic areas, travelers from low-endemicity areas to high-endemicity areas and general population in hyperendemic areas [<xref ref-type="bibr" rid="CR11">11</xref>&#x02022;&#x02022;].</p></sec></sec><sec id="Sec16"><title>Conclusions</title><p id="Par34">Hepatitis E virus leads to outbreaks in developing countries and causes significant morbidity and mortality in immunocompromised and pregnant females. Our knowledge of HEV infection has increased dramatically over the past 20&#x000a0;years. A combination of serology and NAT is the recommended testing strategy for suspected patients. Further research into therapeutic options for treating hepatitis E infection is the need of the hour. Oral ribavirin is the initial drug of choice for severe acute hepatitis, acute-on chronic liver failure, and chronic hepatitis E. PEGylated interferon &#x003b1; can be used for ribavirin-resistant liver transplant patients with chronic hepatitis E. However, no further treatment option is available for immunocompromised organ transplant patients who fail initial ribavirin therapy. Sofosbuvir shows promise as antiviral in immunocompromised patients with chronic hepatitis E, but more evidence would be needed before being considered as a reliable therapeutic option in ribavirin-resistant patients. There is no available treatment option for HEV infection during pregnancy, which takes a very stormy course sometimes. Our further focus should be on finding appropriate management options for HEV infection during pregnancy and for ribavirin-resistant infections.</p></sec></body><back><fn-group><fn><p>This article is part of the Topical Collection on <italic>Hepatitis C</italic></p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author&#x02019;s contribution</title><p>Premashis Kar: conceptualization, planning, literature search, manuscript drafting, revision and editing</p><p>Rahul Karna: literature search, manuscript drafting, revision and editing.</p></notes><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par35">Kar P declares that he has no conflict of interest. Karna R declares that he has no conflict of interest.</p></notes><notes id="FPar2"><title>Human and animal rights and informed consent</title><p id="Par36">This article does not contain any studies with human or animal subjects performed by any of the authors.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref-list id="BSec1"><title>Papers of particular interest, published recently, have been highlighted as: &#x02022; Of importance &#x02022;&#x02022; Of major importance</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>DC</given-names></name><name><surname>Purcell</surname><given-names>RH</given-names></name><name><surname>Sreenivasan</surname><given-names>MA</given-names></name><name><surname>Prasad</surname><given-names>SR</given-names></name><name><surname>Pavri</surname><given-names>KM</given-names></name></person-group><article-title>Epidemic and endemic hepatitis in India: evidence for a non-a, non-B hepatitis virus aetiology</article-title><source>Lancet.</source><year>1980</year><volume>2</volume><issue>8200</issue><fpage>876</fpage><lpage>879</lpage><?supplied-pmid 6107544?><pub-id pub-id-type="pmid">6107544</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name></person-group><article-title>Study of an epidemic of non-a, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-a, non-B type</article-title><source>Am J Med</source><year>1980</year><volume>68</volume><issue>6</issue><fpage>818</fpage><lpage>824</lpage><?supplied-pmid 6770682?><pub-id pub-id-type="pmid">6770682</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balayan</surname><given-names>MS</given-names></name><name><surname>Andjaparidze</surname><given-names>AG</given-names></name><name><surname>Savinskaya</surname><given-names>SS</given-names></name><name><surname>Ketiladze</surname><given-names>ES</given-names></name><name><surname>Braginsky</surname><given-names>DM</given-names></name><name><surname>Savinov</surname><given-names>AP</given-names></name><name><surname>Poleschuk</surname><given-names>VF</given-names></name></person-group><article-title>Evidence for a virus in non-a, non-B hepatitis transmitted via the fecal-oral route</article-title><source>Intervirology.</source><year>1983</year><volume>20</volume><issue>1</issue><fpage>23</fpage><lpage>31</lpage><?supplied-pmid 6409836?><pub-id pub-id-type="pmid">6409836</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name></person-group><article-title>Advances in hepatitis E &#x02013; I: virology, pathogenesis and diagnosis</article-title><source>Expert Rev Gastroent Hepatol</source><year>2016</year><volume>10</volume><issue>9</issue><fpage>1053</fpage><lpage>1063</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Lemon</surname><given-names>SM</given-names></name></person-group><article-title>Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis</article-title><source>Trends Microbiol</source><year>2014</year><volume>22</volume><issue>2</issue><fpage>59</fpage><lpage>64</lpage><?supplied-pmid 24268716?><pub-id pub-id-type="pmid">24268716</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holla</surname><given-names>R</given-names></name><name><surname>Ahmad</surname><given-names>I</given-names></name><name><surname>Ahmad</surname><given-names>Z</given-names></name><name><surname>Jameel</surname><given-names>S</given-names></name></person-group><article-title>Molecular virology of hepatitis E virus</article-title><source>Semin Liver Dis</source><year>2013</year><volume>33</volume><issue>1</issue><fpage>3</fpage><lpage>14</lpage><?supplied-pmid 23564385?><pub-id pub-id-type="pmid">23564385</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guu</surname><given-names>TSY</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Ye</surname><given-names>Q</given-names></name><name><surname>Mata</surname><given-names>DA</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>YJ</given-names></name></person-group><article-title>Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding</article-title><source>PNAS.</source><year>2009</year><volume>106</volume><issue>31</issue><fpage>12992</fpage><lpage>12997</lpage><?supplied-pmid 19622744?><pub-id pub-id-type="pmid">19622744</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hew</surname><given-names>CL</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>N</given-names></name><name><surname>Sivaraman</surname><given-names>J</given-names></name></person-group><article-title>Structural basis for the neutralization and genotype specificity of hepatitis E virus</article-title><source>PNAS.</source><year>2011</year><volume>108</volume><issue>25</issue><fpage>10266</fpage><lpage>10271</lpage><?supplied-pmid 21642534?><pub-id pub-id-type="pmid">21642534</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>SR</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Salunke</surname><given-names>PN</given-names></name><name><surname>Mehrotra</surname><given-names>NN</given-names></name></person-group><article-title>A large waterborne viral hepatitis E epidemic in Kanpur</article-title><source>India Bull World Health Organ</source><year>1992</year><volume>70</volume><issue>5</issue><fpage>597</fpage><lpage>604</lpage><?supplied-pmid 1464145?><pub-id pub-id-type="pmid">1464145</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viswanathan</surname><given-names>R</given-names></name></person-group><article-title>Infectious hepatitis in Delhi (1955-56): a critical study-epidemiology</article-title><source>Indian J Med Res</source><year>1957</year><volume>45</volume><issue>Suppl 1</issue><fpage>1</fpage><lpage>29</lpage><?supplied-pmid 13438536?><pub-id pub-id-type="pmid">13438536</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Pavio</surname><given-names>N</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Labrique</surname><given-names>A</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><etal/></person-group><article-title>Hepatitis E virus infection</article-title><source>Nat Rev Dis Prim</source><year>2017</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>16</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name></person-group><article-title>Advances in hepatitis E &#x02013; II: epidemiology, clinical manifestations, treatment and prevention</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2016</year><volume>10</volume><issue>9</issue><fpage>1065</fpage><lpage>1074</lpage><?supplied-pmid 27148907?><pub-id pub-id-type="pmid">27148907</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rein</surname><given-names>DB</given-names></name><name><surname>Stevens</surname><given-names>GA</given-names></name><name><surname>Theaker</surname><given-names>J</given-names></name><name><surname>Wittenborn</surname><given-names>JS</given-names></name><name><surname>Wiersma</surname><given-names>ST</given-names></name></person-group><article-title>The global burden of hepatitis E virus genotypes 1 and 2 in 2005</article-title><source>Hepatology.</source><year>2012</year><volume>55</volume><issue>4</issue><fpage>988</fpage><lpage>997</lpage><?supplied-pmid 22121109?><pub-id pub-id-type="pmid">22121109</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>Y</given-names></name><name><surname>Oshiro</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Yoshizumi</surname><given-names>T</given-names></name><name><surname>Okajima</surname><given-names>H</given-names></name><name><surname>Ishiyama</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>C</given-names></name><name><surname>Hidaka</surname><given-names>M</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Hibi</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>K</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Kuramitsu</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Tohyama</surname><given-names>T</given-names></name><name><surname>Ikegami</surname><given-names>T</given-names></name><name><surname>Imura</surname><given-names>S</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>Y</given-names></name><name><surname>Urahashi</surname><given-names>T</given-names></name><name><surname>Yamagishi</surname><given-names>K</given-names></name><name><surname>Ohnishi</surname><given-names>H</given-names></name><name><surname>Nagashima</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Shirabe</surname><given-names>K</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Ohkohchi</surname><given-names>N</given-names></name></person-group><article-title>A nationwide survey of hepatitis E virus infection and chronic hepatitis E in liver transplant recipients in Japan</article-title><source>EBioMedicine.</source><year>2015</year><volume>2</volume><issue>11</issue><fpage>1607</fpage><lpage>1612</lpage><?supplied-pmid 26870785?><pub-id pub-id-type="pmid">26870785</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Purdy</surname><given-names>MA</given-names></name></person-group><article-title>Hepatitis E virus genotype 4, Nanjing, China, 2001&#x02013;2011</article-title><source>Emerg Infect Dis</source><year>2013</year><volume>19</volume><issue>9</issue><fpage>1528</fpage><lpage>1530</lpage><?supplied-pmid 23965731?><pub-id pub-id-type="pmid">23965731</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pourbaix</surname><given-names>A</given-names></name><name><surname>Ouali</surname><given-names>N</given-names></name><name><surname>Soussan</surname><given-names>P</given-names></name><name><surname>Afonso</surname><given-names>AMR</given-names></name><name><surname>P&#x000e9;raldi</surname><given-names>M-N</given-names></name><name><surname>Rondeau</surname><given-names>E</given-names></name><etal/></person-group><article-title>Evidence of hepatitis E virus transmission by renal graft</article-title><source>Transpl Infect Dis</source><year>2017</year><volume>19</volume><issue>1</issue><fpage>e12624</fpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Bendall</surname><given-names>R</given-names></name><name><surname>Legrand-Abravanel</surname><given-names>F</given-names></name><name><surname>Xia</surname><given-names>N-S</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Dalton</surname><given-names>HR</given-names></name></person-group><article-title>Hepatitis E</article-title><source>Lancet</source><year>2012</year><volume>379</volume><issue>9835</issue><fpage>2477</fpage><lpage>2488</lpage><?supplied-pmid 22549046?><pub-id pub-id-type="pmid">22549046</pub-id></element-citation></ref><ref id="CR18"><label>18.&#x02022;</label><mixed-citation publication-type="other">Murkey JA, Chew KW, Carlson M, Shannon CL, Sirohi D, Sample HA, et al. Hepatitis E virus&#x02013;associated meningoencephalitis in a lung transplant recipient diagnosed by clinical metagenomic sequencing. Open Forum Infect Dis. 2017;4(3) <bold>First evidence of hepatitis E virus transmission through transplanted lung.</bold></mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satake</surname><given-names>M</given-names></name><name><surname>Matsubayashi</surname><given-names>K</given-names></name><name><surname>Hoshi</surname><given-names>Y</given-names></name><name><surname>Taira</surname><given-names>R</given-names></name><name><surname>Furui</surname><given-names>Y</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><etal/></person-group><article-title>Unique clinical courses of transfusion-transmitted hepatitis E in patients with immunosuppression</article-title><source>Transfusion</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>280</fpage><lpage>288</lpage><?supplied-pmid 28144952?><pub-id pub-id-type="pmid">28144952</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Jiao</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Saldanha</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name></person-group><article-title>Prevalence of hepatitis E virus infection among blood donors in mainland China: a meta-analysis</article-title><source>Transfusion</source><year>2017</year><volume>57</volume><issue>2</issue><fpage>248</fpage><lpage>257</lpage><?supplied-pmid 28035774?><pub-id pub-id-type="pmid">28035774</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>PE</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Brailsford</surname><given-names>SR</given-names></name><name><surname>Brett</surname><given-names>R</given-names></name><name><surname>Dicks</surname><given-names>S</given-names></name><name><surname>Haywood</surname><given-names>B</given-names></name><name><surname>Kennedy</surname><given-names>ITR</given-names></name><name><surname>Kitchen</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Poh</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>K</given-names></name><name><surname>Tettmar</surname><given-names>KI</given-names></name><name><surname>Tossell</surname><given-names>J</given-names></name><name><surname>Ushiro-Lumb</surname><given-names>I</given-names></name><name><surname>Tedder</surname><given-names>RS</given-names></name></person-group><article-title>Hepatitis E virus in blood components: a prevalence and transmission study in Southeast England</article-title><source>Lancet</source><year>2014</year><volume>384</volume><issue>9956</issue><fpage>1766</fpage><lpage>1773</lpage><?supplied-pmid 25078306?><pub-id pub-id-type="pmid">25078306</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name><name><surname>Jameel</surname><given-names>S</given-names></name></person-group><article-title>Vertical transmission of hepatitis E virus</article-title><source>Lancet.</source><year>1995</year><volume>345</volume><issue>8956</issue><fpage>1025</fpage><lpage>1026</lpage><?supplied-pmid 7723501?><pub-id pub-id-type="pmid">7723501</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>RM</given-names></name><name><surname>Uduman</surname><given-names>S</given-names></name><name><surname>Rana</surname><given-names>S</given-names></name><name><surname>Kochiyil</surname><given-names>JK</given-names></name><name><surname>Usmani</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name></person-group><article-title>Sero-prevalence and mother-to-infant transmission of hepatitis E virus among pregnant women in the United Arab Emirates</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2001</year><volume>100</volume><issue>1</issue><fpage>9</fpage><lpage>15</lpage><?supplied-pmid 11728649?><pub-id pub-id-type="pmid">11728649</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>EASL</collab></person-group><article-title>Clinical Practice Guidelines on hepatitis E virus infection</article-title><source>J Hepatol</source><year>2018</year><volume>68</volume><issue>6</issue><fpage>1256</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">29609832</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Aggarwal D, R. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol. 2013;10(1):24&#x02013;33.</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norder</surname><given-names>H</given-names></name><name><surname>Karlsson</surname><given-names>M</given-names></name><name><surname>Mellgren</surname><given-names>&#x000c5;</given-names></name><name><surname>Konar</surname><given-names>J</given-names></name><name><surname>Sandberg</surname><given-names>E</given-names></name><name><surname>Lasson</surname><given-names>A</given-names></name><name><surname>Castedal</surname><given-names>M</given-names></name><name><surname>Magnius</surname><given-names>L</given-names></name><name><surname>Lagging</surname><given-names>M</given-names></name></person-group><article-title>Diagnostic performance of five assays for anti-hepatitis E virus IgG and IgM in a large cohort study</article-title><source>J Clin Microbiol</source><year>2016</year><volume>54</volume><issue>3</issue><fpage>549</fpage><lpage>555</lpage><?supplied-pmid 26659210?><pub-id pub-id-type="pmid">26659210</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name><name><surname>Dar</surname><given-names>MY</given-names></name><name><surname>Moecklii</surname><given-names>R</given-names></name><name><surname>Jameel</surname><given-names>S</given-names></name></person-group><article-title>Hepatitis E and long-term antibody status</article-title><source>Lancet.</source><year>1993</year><volume>341</volume><issue>8856</issue><fpage>1355</fpage><?supplied-pmid 8098491?><pub-id pub-id-type="pmid">8098491</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myint</surname><given-names>KSA</given-names></name><name><surname>Endy</surname><given-names>TP</given-names></name><name><surname>Shrestha</surname><given-names>MP</given-names></name><name><surname>Shrestha</surname><given-names>SK</given-names></name><name><surname>Vaughn</surname><given-names>DW</given-names></name><name><surname>Innis</surname><given-names>BL</given-names></name><name><surname>Gibbons</surname><given-names>RV</given-names></name><name><surname>Kuschner</surname><given-names>RA</given-names></name><name><surname>Seriwatana</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>RMN</given-names></name></person-group><article-title>Hepatitis E antibody kinetics in Nepalese patients</article-title><source>Trans R Soc Trop Med Hyg</source><year>2006</year><volume>100</volume><issue>10</issue><fpage>938</fpage><lpage>941</lpage><?supplied-pmid 16542692?><pub-id pub-id-type="pmid">16542692</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Chapuy-Regaud</surname><given-names>S</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Miedoug&#x000e9;</surname><given-names>M</given-names></name><name><surname>Peron</surname><given-names>J-M</given-names></name><name><surname>Alric</surname><given-names>L</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients</article-title><source>J Clin Virol</source><year>2013</year><volume>58</volume><issue>4</issue><fpage>624</fpage><lpage>628</lpage><?supplied-pmid 24183927?><pub-id pub-id-type="pmid">24183927</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendall</surname><given-names>R</given-names></name><name><surname>Ellis</surname><given-names>V</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name><name><surname>Dalton</surname><given-names>H</given-names></name></person-group><article-title>A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries</article-title><source>J Med Virol</source><year>2010</year><volume>82</volume><issue>5</issue><fpage>799</fpage><lpage>805</lpage><?supplied-pmid 20336757?><pub-id pub-id-type="pmid">20336757</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Chapuy-Regaud</surname><given-names>S</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Muscari</surname><given-names>F</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name></person-group><article-title>Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections</article-title><source>J Infect Dis</source><year>2014</year><volume>209</volume><issue>12</issue><fpage>1900</fpage><lpage>1906</lpage><?supplied-pmid 24436450?><pub-id pub-id-type="pmid">24436450</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myint</surname><given-names>KSA</given-names></name><name><surname>Guan</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Howard</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evaluation of a new rapid immunochromatographic assay for serodiagnosis of acute hepatitis E infection</article-title><source>Amn J Trop Med Hyg</source><year>2005</year><volume>73</volume><issue>5</issue><fpage>942</fpage><lpage>946</lpage></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legrand-Abravanel</surname><given-names>F</given-names></name><name><surname>Thevenet</surname><given-names>I</given-names></name><name><surname>Mansuy</surname><given-names>J-M</given-names></name><name><surname>Saune</surname><given-names>K</given-names></name><name><surname>Vischi</surname><given-names>F</given-names></name><name><surname>Peron</surname><given-names>J-M</given-names></name><etal/></person-group><article-title>Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections</article-title><source>Clin Vaccine Immunol</source><year>2009</year><volume>16</volume><issue>5</issue><fpage>772</fpage><lpage>774</lpage><?supplied-pmid 19321696?><pub-id pub-id-type="pmid">19321696</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yin</surname><given-names>XP</given-names></name><name><surname>Li</surname><given-names>XR</given-names></name><name><surname>Liu</surname><given-names>JX</given-names></name></person-group><article-title>Reverse transcription-loop-mediated isothermal amplification assay for rapid detection of hepatitis E virus</article-title><source>J Clin Microbiol</source><year>2009</year><volume>47</volume><issue>7</issue><fpage>2304</fpage><lpage>2306</lpage><?supplied-pmid 19403760?><pub-id pub-id-type="pmid">19403760</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauleda</surname><given-names>S</given-names></name><name><surname>Ong</surname><given-names>E</given-names></name><name><surname>Bes</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>A</given-names></name><name><surname>Cory</surname><given-names>R</given-names></name><name><surname>Babizki</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Lindquist</surname><given-names>A</given-names></name><name><surname>Hoang</surname><given-names>A</given-names></name><name><surname>Vang</surname><given-names>L</given-names></name><name><surname>Piron</surname><given-names>M</given-names></name><name><surname>Casamitjana</surname><given-names>N</given-names></name><name><surname>Koppelman</surname><given-names>M</given-names></name><name><surname>Danzig</surname><given-names>L</given-names></name><name><surname>Linnen</surname><given-names>JM</given-names></name></person-group><article-title>Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain)</article-title><source>Transfusion</source><year>2015</year><volume>55</volume><issue>5</issue><fpage>972</fpage><lpage>979</lpage><?supplied-pmid 25403913?><pub-id pub-id-type="pmid">25403913</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baylis</surname><given-names>SA</given-names></name><name><surname>Hanschmann</surname><given-names>K-M</given-names></name><name><surname>Bl&#x000fc;mel</surname><given-names>J</given-names></name><name><surname>N&#x000fc;bling</surname><given-names>CM</given-names></name></person-group><article-title>Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance</article-title><source>J Clin Microbiol</source><year>2011</year><volume>49</volume><issue>4</issue><fpage>1234</fpage><lpage>1239</lpage><?supplied-pmid 21307208?><pub-id pub-id-type="pmid">21307208</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Chapuy-Regaud</surname><given-names>S</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Dubois</surname><given-names>M</given-names></name><name><surname>Peron</surname><given-names>J-M</given-names></name><name><surname>Alric</surname><given-names>L</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name></person-group><article-title>Performance of two commercial assays for detecting hepatitis E virus RNA in acute or chronic infections</article-title><source>J Clin Microbiol</source><year>2013</year><volume>51</volume><issue>6</issue><fpage>1913</fpage><lpage>1916</lpage><?supplied-pmid 23515544?><pub-id pub-id-type="pmid">23515544</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tr&#x000e9;meaux</surname><given-names>P</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Chapuy-Regaud</surname><given-names>S</given-names></name><name><surname>Peron</surname><given-names>J-M</given-names></name><name><surname>Alric</surname><given-names>L</given-names></name><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name></person-group><article-title>Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection</article-title><source>J Clin Virol</source><year>2016</year><volume>79</volume><fpage>1</fpage><lpage>5</lpage><?supplied-pmid 27038538?><pub-id pub-id-type="pmid">27038538</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Harrison</surname><given-names>TJ</given-names></name><name><surname>Chong</surname><given-names>H</given-names></name><name><surname>Qiao</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhuang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E</article-title><source>J Med Virol</source><year>2006</year><volume>78</volume><issue>11</issue><fpage>1441</fpage><lpage>1448</lpage><?supplied-pmid 16998897?><pub-id pub-id-type="pmid">16998897</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalimar</surname><given-names>KS</given-names></name><name><surname>Gunjan</surname><given-names>D</given-names></name><name><surname>Sonika</surname><given-names>U</given-names></name><name><surname>Mahapatra</surname><given-names>SJ</given-names></name><name><surname>Nayak</surname><given-names>B</given-names></name><etal/></person-group><article-title>Acute liver failure due to hepatitis E virus infection is associated with better survival than other etiologies in Indian patients</article-title><source>Dig Dis Sci</source><year>2017</year><volume>62</volume><issue>4</issue><fpage>1058</fpage><lpage>1066</lpage><?supplied-pmid 28130708?><pub-id pub-id-type="pmid">28130708</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debing</surname><given-names>Y</given-names></name><name><surname>Emerson</surname><given-names>SU</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Balzarini</surname><given-names>J</given-names></name><name><surname>Dallmeier</surname><given-names>K</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name></person-group><article-title>Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>1</issue><fpage>267</fpage><lpage>273</lpage><?supplied-pmid 24145541?><pub-id pub-id-type="pmid">24145541</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paeshuyse</surname><given-names>J</given-names></name><name><surname>Dallmeier</surname><given-names>K</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name></person-group><article-title>Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action</article-title><source>Curr Opin Virol</source><year>2011</year><volume>1</volume><issue>6</issue><fpage>590</fpage><lpage>598</lpage><?supplied-pmid 22440916?><pub-id pub-id-type="pmid">22440916</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerolami</surname><given-names>R</given-names></name><name><surname>Borentain</surname><given-names>P</given-names></name><name><surname>Raissouni</surname><given-names>F</given-names></name><name><surname>Motte</surname><given-names>A</given-names></name><name><surname>Solas</surname><given-names>C</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name></person-group><article-title>Treatment of severe acute hepatitis E by ribavirin</article-title><source>J Clin Virol</source><year>2011</year><volume>52</volume><issue>1</issue><fpage>60</fpage><lpage>62</lpage><?supplied-pmid 21764632?><pub-id pub-id-type="pmid">21764632</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Panda</surname><given-names>SK</given-names></name><name><surname>Paul</surname><given-names>SB</given-names></name><name><surname>Acharya</surname><given-names>SK</given-names></name></person-group><article-title>Ribavirin therapy for hepatitis E virus-induced acute on chronic liver failure: a preliminary report</article-title><source>Antivir Ther</source><year>2012</year><volume>17</volume><issue>6</issue><fpage>1091</fpage><lpage>1096</lpage><?supplied-pmid 22910532?><pub-id pub-id-type="pmid">22910532</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Selves</surname><given-names>J</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Ouezzani</surname><given-names>L</given-names></name><name><surname>P&#x000e9;ron</surname><given-names>JM</given-names></name><name><surname>Guitard</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis E virus and chronic hepatitis in organ-transplant recipients</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>8</issue><fpage>811</fpage><lpage>817</lpage><?supplied-pmid 18287603?><pub-id pub-id-type="pmid">18287603</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ollier</surname><given-names>L</given-names></name><name><surname>Tieulie</surname><given-names>N</given-names></name><name><surname>Sanderson</surname><given-names>F</given-names></name><name><surname>Heudier</surname><given-names>P</given-names></name><name><surname>Giordanengo</surname><given-names>V</given-names></name><name><surname>Fuzibet</surname><given-names>J-G</given-names></name><name><surname>Nicand</surname><given-names>E</given-names></name></person-group><article-title>Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab</article-title><source>Ann Intern Med</source><year>2009</year><volume>150</volume><issue>6</issue><fpage>430</fpage><lpage>431</lpage><?supplied-pmid 19293084?><pub-id pub-id-type="pmid">19293084</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>HR</given-names></name><name><surname>Bendall</surname><given-names>RP</given-names></name><name><surname>Keane</surname><given-names>FE</given-names></name><name><surname>Tedder</surname><given-names>RS</given-names></name><name><surname>Ijaz</surname><given-names>S</given-names></name></person-group><article-title>Persistent carriage of hepatitis E virus in patients with HIV infection</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><issue>10</issue><fpage>1025</fpage><lpage>1027</lpage><?supplied-pmid 19726781?><pub-id pub-id-type="pmid">19726781</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Cointault</surname><given-names>O</given-names></name><name><surname>Selves</surname><given-names>J</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Danjoux</surname><given-names>M</given-names></name></person-group><article-title>Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><issue>8</issue><fpage>1744</fpage><lpage>1748</lpage><?supplied-pmid 18557740?><pub-id pub-id-type="pmid">18557740</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Garrouste</surname><given-names>C</given-names></name><name><surname>Haagsma</surname><given-names>EB</given-names></name><name><surname>Garrigue</surname><given-names>V</given-names></name><name><surname>Pischke</surname><given-names>S</given-names></name><name><surname>Chauvet</surname><given-names>C</given-names></name><name><surname>Dumortier</surname><given-names>J</given-names></name><name><surname>Cannesson</surname><given-names>A</given-names></name><name><surname>Cassuto&#x02013;Viguier</surname><given-names>E</given-names></name><name><surname>Thervet</surname><given-names>E</given-names></name><name><surname>Conti</surname><given-names>F</given-names></name><name><surname>Lebray</surname><given-names>P</given-names></name><name><surname>Dalton</surname><given-names>HR</given-names></name><name><surname>Santella</surname><given-names>R</given-names></name><name><surname>Kanaan</surname><given-names>N</given-names></name><name><surname>Essig</surname><given-names>M</given-names></name><name><surname>Mousson</surname><given-names>C</given-names></name><name><surname>Radenne</surname><given-names>S</given-names></name><name><surname>Roque&#x02013;Afonso</surname><given-names>AM</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name></person-group><article-title>Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants</article-title><source>Gastroenterology</source><year>2011</year><volume>140</volume><issue>5</issue><fpage>1481</fpage><lpage>1489</lpage><?supplied-pmid 21354150?><pub-id pub-id-type="pmid">21354150</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borentain</surname><given-names>P</given-names></name><name><surname>Colson</surname><given-names>P</given-names></name><name><surname>Bolon</surname><given-names>E</given-names></name><name><surname>Gauchez</surname><given-names>P</given-names></name><name><surname>Coso</surname><given-names>D</given-names></name><name><surname>Gerolami</surname><given-names>R</given-names></name></person-group><article-title>Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><issue>1</issue><fpage>446</fpage><lpage>448</lpage><?supplied-pmid 28873236?><pub-id pub-id-type="pmid">28873236</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Tripon</surname><given-names>S</given-names></name><name><surname>Bismuth</surname><given-names>M</given-names></name><name><surname>Hillaire</surname><given-names>S</given-names></name><name><surname>Dumortier</surname><given-names>J</given-names></name><name><surname>Radenne</surname><given-names>S</given-names></name><name><surname>Coilly</surname><given-names>A</given-names></name><name><surname>Garrigue</surname><given-names>V</given-names></name><name><surname>D'Alteroche</surname><given-names>L</given-names></name><name><surname>Buchler</surname><given-names>M</given-names></name><name><surname>Couzi</surname><given-names>L</given-names></name><name><surname>Lebray</surname><given-names>P</given-names></name><name><surname>Dharancy</surname><given-names>S</given-names></name><name><surname>Minello</surname><given-names>A</given-names></name><name><surname>Hourmant</surname><given-names>M</given-names></name><name><surname>Roque-Afonso</surname><given-names>AM</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Pol</surname><given-names>S</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Mallet</surname><given-names>V</given-names></name></person-group><article-title>Ribavirin for chronic hepatitis E virus infection in transplant recipients</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>12</issue><fpage>1111</fpage><lpage>1120</lpage><?supplied-pmid 24645943?><pub-id pub-id-type="pmid">24645943</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Lhomme</surname><given-names>S</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Cointault</surname><given-names>O</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><name><surname>Cardeau-Desangles</surname><given-names>I</given-names></name></person-group><article-title>An early viral response predicts the virological response to ribavirin in hepatitis E virus organ transplant patients</article-title><source>Transplantation.</source><year>2015</year><volume>99</volume><issue>10</issue><fpage>2124</fpage><lpage>2131</lpage><?supplied-pmid 26214817?><pub-id pub-id-type="pmid">26214817</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Chatelut</surname><given-names>E</given-names></name><name><surname>Manolis</surname><given-names>E</given-names></name><name><surname>Lafont</surname><given-names>T</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name></person-group><article-title>Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>43</volume><issue>1</issue><fpage>140</fpage><lpage>146</lpage><?supplied-pmid 14712437?><pub-id pub-id-type="pmid">14712437</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Debing Y, Gisa A, Dallmeier K, Pischke S, Bremer B, Manns M, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology. 2014;147(5):1008&#x02013;1011.e7 quiz e15&#x02013;16.</mixed-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Debing</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Van Der Laan</surname><given-names>LJW</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><etal/></person-group><article-title>Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus</article-title><source>Gastroenterology.</source><year>2014</year><volume>146</volume><issue>7</issue><fpage>1775</fpage><lpage>1783</lpage><?supplied-pmid 24582714?><pub-id pub-id-type="pmid">24582714</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dao Thi</surname><given-names>VL</given-names></name><name><surname>Debing</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Moradpour</surname><given-names>D</given-names></name><etal/></person-group><article-title>Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><issue>1</issue><fpage>82</fpage><lpage>85.e4</lpage><?supplied-pmid 26408347?><pub-id pub-id-type="pmid">26408347</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Valk</surname><given-names>M</given-names></name><name><surname>Zaaijer</surname><given-names>HL</given-names></name><name><surname>Kater</surname><given-names>AP</given-names></name><name><surname>Schinkel</surname><given-names>J</given-names></name></person-group><article-title>Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection</article-title><source>J Hepatol</source><year>2017</year><volume>66</volume><issue>1</issue><fpage>242</fpage><lpage>243</lpage><?supplied-pmid 27702641?><pub-id pub-id-type="pmid">27702641</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">van Wezel EM, de Bruijne J, Damman K, Bijmolen M, van den Berg AP, Verschuuren EAM, et al. Sofosbuvir add-on to ribavirin treatment for chronic hepatitis E virus infection in solid organ transplant recipients does not result in sustained virological response. Open Forum Infect Dis. 2019;6(8).</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Garrouste</surname><given-names>C</given-names></name><name><surname>Esposito</surname><given-names>L</given-names></name><name><surname>Cardeau-Desangles</surname><given-names>I</given-names></name></person-group><article-title>Pegylated interferon-&#x003b1; for treating chronic hepatitis E virus infection after liver transplantation</article-title><source>Clin Infect Dis</source><year>2010</year><volume>50</volume><issue>5</issue><fpage>e30</fpage><lpage>e33</lpage><pub-id pub-id-type="pmid">20113176</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamar</surname><given-names>N</given-names></name><name><surname>Abravanel</surname><given-names>F</given-names></name><name><surname>Garrouste</surname><given-names>C</given-names></name><name><surname>Cardeau-Desangles</surname><given-names>I</given-names></name><name><surname>Mansuy</surname><given-names>JM</given-names></name><name><surname>Weclawiak</surname><given-names>H</given-names></name></person-group><article-title>Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><issue>8</issue><fpage>2792</fpage><lpage>2795</lpage><?supplied-pmid 20494897?><pub-id pub-id-type="pmid">20494897</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haagsma</surname><given-names>EB</given-names></name><name><surname>Riezebos-Brilman</surname><given-names>A</given-names></name><name><surname>van den Berg</surname><given-names>AP</given-names></name><name><surname>Porte</surname><given-names>RJ</given-names></name><name><surname>Niesters</surname><given-names>HG</given-names></name></person-group><article-title>Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b</article-title><source>Liver Transpl</source><year>2010</year><volume>16</volume><issue>4</issue><fpage>474</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">20373458</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostaing</surname><given-names>L</given-names></name><name><surname>Izopet</surname><given-names>J</given-names></name><name><surname>Baron</surname><given-names>E</given-names></name><name><surname>Duffaut</surname><given-names>M</given-names></name><name><surname>Puel</surname><given-names>J</given-names></name><name><surname>Durand</surname><given-names>D</given-names></name></person-group><article-title>Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients</article-title><source>Transplantation.</source><year>1995</year><volume>59</volume><issue>10</issue><fpage>1426</fpage><lpage>1431</lpage><?supplied-pmid 7770930?><pub-id pub-id-type="pmid">7770930</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manka</surname><given-names>P</given-names></name><name><surname>Bechmann</surname><given-names>LP</given-names></name><name><surname>Coombes</surname><given-names>JD</given-names></name><name><surname>Thodou</surname><given-names>V</given-names></name><name><surname>Schlattjan</surname><given-names>M</given-names></name><name><surname>Kahraman</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hepatitis E virus infection as a possible cause of acute liver failure in Europe</article-title><source>Clin Gastroenterol Hepatol</source><year>2015</year><volume>13</volume><issue>10</issue><fpage>1836</fpage><lpage>1842.e2</lpage><?supplied-pmid 25912835?><pub-id pub-id-type="pmid">25912835</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>P</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name></person-group><article-title>A guide to the management of hepatitis E infection during pregnancy</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2019</year><volume>13</volume><issue>3</issue><fpage>205</fpage><lpage>211</lpage><?supplied-pmid 30791760?><pub-id pub-id-type="pmid">30791760</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karna</surname><given-names>R</given-names></name><name><surname>Hazam</surname><given-names>RK</given-names></name><name><surname>Borkakoti</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kar</surname><given-names>P</given-names></name></person-group><article-title>A 5-year single-center experience of hepatitis E virus infection during pregnancy</article-title><source>J Clin Exp Hepatol</source><year>2020</year><volume>10</volume><issue>2</issue><fpage>135</fpage><lpage>138</lpage><?supplied-pmid 32189928?><pub-id pub-id-type="pmid">32189928</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranger-Rogez</surname><given-names>S</given-names></name><name><surname>Alain</surname><given-names>S</given-names></name><name><surname>Denis</surname><given-names>F</given-names></name></person-group><article-title>Hepatitis viruses: mother to child transmission</article-title><source>Pathol Biol (Paris)</source><year>2002</year><volume>50</volume><issue>9</issue><fpage>568</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">12490422</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuroo</surname><given-names>MS</given-names></name><name><surname>Kamili</surname><given-names>S</given-names></name></person-group><article-title>Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy</article-title><source>J Viral Hepat</source><year>2003</year><volume>10</volume><issue>1</issue><fpage>61</fpage><lpage>69</lpage><?supplied-pmid 12558914?><pub-id pub-id-type="pmid">12558914</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoszek</surname><given-names>SK</given-names></name><name><surname>Abdel-Hamid</surname><given-names>M</given-names></name><name><surname>Saleh</surname><given-names>DA</given-names></name><name><surname>Kafrawy</surname><given-names>SE</given-names></name><name><surname>Narooz</surname><given-names>S</given-names></name><name><surname>Hawash</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High prevalence of hepatitis E antibodies in pregnant Egyptian women</article-title><source>Trans R Soc Trop Med Hyg</source><year>2006</year><volume>100</volume><issue>2</issue><fpage>95</fpage><lpage>101</lpage><?supplied-pmid 16257426?><pub-id pub-id-type="pmid">16257426</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krain</surname><given-names>LJ</given-names></name><name><surname>Atwell</surname><given-names>JE</given-names></name><name><surname>Nelson</surname><given-names>KE</given-names></name><name><surname>Labrique</surname><given-names>AB</given-names></name></person-group><article-title>Fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection</article-title><source>Am J Trop Med Hyg</source><year>2014</year><volume>90</volume><issue>2</issue><fpage>365</fpage><lpage>370</lpage><?supplied-pmid 24420778?><pub-id pub-id-type="pmid">24420778</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Trivedi</surname><given-names>SS</given-names></name><name><surname>Puri</surname><given-names>M</given-names></name><name><surname>Sarin</surname><given-names>SK</given-names></name></person-group><article-title>Maternal and fetal outcomes in HEV-infected pregnant women</article-title><source>Ann Intern Med</source><year>2007</year><volume>147</volume><issue>1</issue><fpage>28</fpage><lpage>33</lpage><?supplied-pmid 17606958?><pub-id pub-id-type="pmid">17606958</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasheeda</surname><given-names>CA</given-names></name><name><surname>Navaneethan</surname><given-names>U</given-names></name><name><surname>Jayanthi</surname><given-names>V</given-names></name></person-group><article-title>Liver disease in pregnancy and its influence on maternal and fetal mortality: a prospective study from Chennai, Southern India</article-title><source>Eur J Gastroenterol Hepatol</source><year>2008</year><volume>20</volume><issue>4</issue><fpage>362</fpage><lpage>364</lpage><?supplied-pmid 18334884?><pub-id pub-id-type="pmid">18334884</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayis</surname><given-names>DA</given-names></name><name><surname>Jumaa</surname><given-names>AM</given-names></name><name><surname>Gasim</surname><given-names>GI</given-names></name><name><surname>Karsany</surname><given-names>MS</given-names></name><name><surname>Adam</surname><given-names>I</given-names></name></person-group><article-title>An outbreak of hepatitis E and high maternal mortality at Port Sudan</article-title><source>Eastern Sudan Pathogens and Global Health</source><year>2013</year><volume>107</volume><issue>2</issue><fpage>66</fpage><lpage>68</lpage><?supplied-pmid 23683332?><pub-id pub-id-type="pmid">23683332</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banait</surname><given-names>VS</given-names></name><name><surname>Sandur</surname><given-names>V</given-names></name><name><surname>Parikh</surname><given-names>F</given-names></name><name><surname>Murugesh</surname><given-names>M</given-names></name><name><surname>Ranka</surname><given-names>P</given-names></name><name><surname>Ramesh</surname><given-names>VS</given-names></name></person-group><article-title>Outcome of acute liver failure due to acute hepatitis E in pregnant women</article-title><source>Indian J Gastroenterol</source><year>2007</year><volume>26</volume><issue>1</issue><fpage>6</fpage><lpage>10</lpage><?supplied-pmid 17401226?><pub-id pub-id-type="pmid">17401226</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name><name><surname>Li</surname><given-names>T-C</given-names></name><name><surname>Yasutomi</surname><given-names>Y</given-names></name><name><surname>Lara</surname><given-names>J</given-names></name><name><surname>Khudyakov</surname><given-names>Y</given-names></name><name><surname>Schofield</surname><given-names>D</given-names></name><name><surname>Emerson</surname><given-names>SU</given-names></name><name><surname>Purcell</surname><given-names>RH</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><name><surname>Miyamura</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>RH</given-names></name></person-group><article-title>Spatial configuration of hepatitis E virus antigenic domain</article-title><source>J Virol</source><year>2011</year><volume>85</volume><issue>2</issue><fpage>1117</fpage><lpage>1124</lpage><?supplied-pmid 21068233?><pub-id pub-id-type="pmid">21068233</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>MP</given-names></name><name><surname>Scott</surname><given-names>RM</given-names></name><name><surname>Joshi</surname><given-names>DM</given-names></name><name><surname>Mammen</surname><given-names>MP</given-names><suffix>Jr</suffix></name><name><surname>Thapa</surname><given-names>GB</given-names></name><name><surname>Thapa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Safety and efficacy of a recombinant hepatitis E vaccine</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>9</issue><fpage>895</fpage><lpage>903</lpage><?supplied-pmid 17329696?><pub-id pub-id-type="pmid">17329696</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>F-C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X-F</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Z-Z</given-names></name><name><surname>Huang</surname><given-names>S-J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>CL</given-names></name><name><surname>Jiang</surname><given-names>HM</given-names></name><name><surname>Cai</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Ai</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>YM</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Xian</surname><given-names>YL</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Shih</surname><given-names>JWK</given-names></name><name><surname>Xia</surname><given-names>NS</given-names></name></person-group><article-title>Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9744</issue><fpage>895</fpage><lpage>902</lpage><?supplied-pmid 20728932?><pub-id pub-id-type="pmid">20728932</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name><name><surname>Huang</surname><given-names>SJ</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>YM</given-names></name><name><surname>Wang</surname><given-names>ZZ</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Li</surname><given-names>JX</given-names></name><name><surname>Yang</surname><given-names>CL</given-names></name><name><surname>Tang</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>RJ</given-names></name><name><surname>Pan</surname><given-names>HR</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Shih</surname><given-names>JWK</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Zhu</surname><given-names>FC</given-names></name><name><surname>Xia</surname><given-names>NS</given-names></name></person-group><article-title>Long-term efficacy of a hepatitis E vaccine</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>10</issue><fpage>914</fpage><lpage>922</lpage><?supplied-pmid 25738667?><pub-id pub-id-type="pmid">25738667</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other">Organization WH. Global Advisory Committee on Vaccine Safety, 11&#x02013;12 June 2014 = Comit&#x000e9; consultatif mondial de la S&#x000e9;curit&#x000e9; vaccinale, 11&#x02013;12 juin 2014. Weekly Epidemiological Record = Relev&#x000e9; &#x000e9;pid&#x000e9;miologique hebdomadaire. 2014;89(29):325&#x02013;35.</mixed-citation></ref></ref-list></ref-list></back></article>